ITI-007
ITI-007 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 71.4%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
71.4%
5 of 7 finished
28.6%
2 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
A Trial to Assess the Antipsychotic Efficacy of ITI-007
ITI-007 (Lumateperone Tosylate) for Schizophrenia
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Clinical Trials (7)
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
A Trial to Assess the Antipsychotic Efficacy of ITI-007
ITI-007 (Lumateperone Tosylate) for Schizophrenia
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7